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Abstract
The insulin-like growth factor axis, which has been shown to
protect cells from apoptosis, plays an essential role in normal cell
physiology and in cancer development. The family of insulin-like
growth factor binding proteins (IGFBPs) has been shown to have a
diverse spectrum of functions in cell growth, death, motility, and
tissue remodeling. Among the six IGFBP family members, IGFBP-5
has recently been shown to play an important role in the biology of
breast cancer, especially in breast cancer metastasis; however, the
exact mechanisms of action remain obscure and sometimes
paradoxical. An in-depth understanding of IGFBP-5 would shed
light on its potential role as a target for breast cancer therapeutics.
Introduction
There are six well-characterized insulin-like growth factor binding
proteins (IGFBP-1 to IGFBP-6) isolated and characterized from
a variety of vertebrate species, including humans; the IGFBPs
range in size from 216 to 289 amino acids, with molecular
masses between 24 and 44 kDa [1,2]. These IGFBPs share a
highly conserved protein domain structure consisting of three
main parts (N, L, and C domains). The N and C domains contain
insulin-like growth factor (IGF)-binding sites, and the L domain
carries proteolytic degradation sites. Some other putative IGF-
binding proteins with less sequence homology have been
found, but they have not been well studied [3].
IGFBPs are traditionally known as carrier proteins that regu-
late the activity of IGFs by prolonging their half-life and their
circulation turnover [4]. The important role of IGFBPs in
cellular metabolism is apparent because of their association
and the regulation of a key signaling pathway triggered by
IGF-I and IGF-II. The IGFs have been well documented to
play a crucial role in cellular growth, differentiation, and apop-
tosis [5,6]. The IGF pathway has been shown to be activated
in many cancer types, including breast cancer [7-9]. IGF
binds to two types of receptors, IGF-IR and IGF-IIR, on cell
membranes, and activates the tyrosine kinase pathway
downstream [4,10]. Binding of IGFBP proteins with IGF has
been shown to either positively or negatively regulate the
binding of IGFs to their receptors [1], thus directly affecting
the IGF signaling pathways.
Numerous studies, however, have found that IGFBPs also
function independently of the IGF signaling pathway. IGFBPs
may interact with proteins other than IGFs, may be cleaved,
may bind to their own receptor on the membrane, and may
locate both extracellularly and intracellularly [11]. Importantly,
there is increasing evidence that IGFBP-2, IGFBP-3, and
IGFBP-5 are important players in the phenotypes of various
cancers [2,12,13]. Pertinent to the present review, IGFBP-5
has been associated with breast metastasis [9,14].
In the present article, we review literature reports on the
functions and regulation of IGFBP-5, and particularly their
potential role in breast cancer development and progression.
IGFBP-5 gene and protein
IGFBP-5 was first cloned in 1993 [15], and its genomic
structure was characterized in 1994 by Allander and
colleagues [16]. The IGFBP-5 gene has a length of 33 kb
and is located on chromosome 2 in humans. This gene, which
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has four exons, encodes a soluble protein of approximately
29 kDa expressed in various types of tissues in humans. The
IGFBP-5 gene is located on the same chromosome as the
IGFBP-2 gene but is oriented in a tail-to-tail fashion (opposite
direction of transcription). The IGFBP-1 and IGFBP-3 genes
also show the same structural orientation on chromosome 7
[17]. These structural relationships between IGFBP genes
suggest that these genes developed after duplication of an
ancestral IGFBP gene.
IGFBPs share a common domain organization. A schematic
representation of the IGFBP-5 domain structure is shown in
Figure 1. IGFBP-5 has several features that suggest it is a
key component of the IGF system. IGFBP-5 contains a leader
or signal peptide (first 20 residues) that allows its secretion
from the cytoplasm to the extracellular matrix (ECM).
N domain
The IGFBP-5 protein contains 18 conserved cysteine residues,
of which 12 are located in the N-terminal domain and the
others in the C-terminal domain. Using nuclear magnetic
resonance spectroscopy, Kalus and colleagues examined the
N-terminal fragments of IGFBP-5 [18]. They found that the
primary binding site for IGFs is located between Ala40 and
Ile92, termed mini-IGFBP-5, which has a rigid globular
structure consisting of a centrally located three-stranded
antiparallel β-sheet and contains two internal disulfide bonds
(Cys47–Cys60 and Cys54–Cys80). The main residues for
IGF-binding sites are Val49, Tyr50, Pro62, and Lys68 to Leu75
located in the mini-IGFBP-5 sequence. Mutagenesis studies
have shown that residues Lys68, Pro69, Leu70, Leu73, and
Leu74 in the N-terminal region of IGFBP-5 are the most critical
amino acids for high-affinity binding to IGF-I [19].
L domain
The midregion of IGFBP-5 (L domain) is less conserved
compared with the N and C domains and contains post-
translational modification sites for glycosylation, phosphory-
lation, and proteolysis. These post-transcriptional modifica-
tions might play important roles in protein interactions, the
protein half-life, and the proteolysis potential. Structural
characterization studies have revealed O-glycosylation
[20,21] and serine phosphorylation sites for IGFBP-5 [22].
The functional role of these modifications is unclear, but it has
been postulated that these modifications may affect the
interaction with IGFs, the acid-labile subunit, and cell surface
or matrix components [23]. Proteolytic degradation of
IGFBPs into fragments reduces their affinity for IGFs,
increases the concentration of free IGFs at the cell surface,
and activates the IGF receptor signaling pathway.
Most of the proteolytic sites of IGFBP-5 determined so far
are located in the L domain. Several different proteases that
specifically degrade IGFBP-5 have been identified [24].
Serine proteases (complement protein 1s) [25], metallo-
proteinases (MMP-1) [26], ADAM 12S [27], PAPP-A2 [28]
and cathepsins (cathepsin D) [29] are the members of the
IGFBP-5-degrading proteinases. Through the functions of
these proteases, IGFBP-5 degradation can be regulated in a
tissue-specific manner.
C domain
Another critical and functionally effective domain of IGFBP-5
is its C-terminal domain. This domain contains a region
(amino acids 201 to 218) that shares strong sequence homo-
logy with a previously identified nuclear localization sequence
(NLS) [30]. Among the six IGFBPs, only IGFBP-3 and
IGFBP-5 have a nuclear localization sequence. The NLS is
located between amino acids 215 and 232 for IGFBP-3.
Studies from Schedlich and her coworkers have demon-
strated the importance of the NLS of IGFBP-5 in cytoplasmic
and nuclear trafficking [31,32]. They observed nuclear
localization using fluorescently labeled IGFBP-3 and IGFBP-5
in the T47D cell line [31]. In addition, these researchers
showed that transportation of IGFBP-5 depends on its NLS
and is not affected by blocking of the receptor-mediated
Figure 1
Domain structure of insulin-like growth factor binding protein 5 and potential functional effects. ALS, acid-labile subunit; ECM, extracellular matrix;
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endocytosis. More recently, the same group showed that
importin-β binds IGFBP-5 and is responsible for the nuclear
transport of IGFBP-5 [32]. More in-depth studies will be
needed to understand the effect of IGFBP-5 cellular localiza-
tion on its physiological functions and the role of this spatial
regulation in breast cancer pathobiology.
Recently, Jurgeit and colleagues studied nuclear and
cytoplasmic trafficking and localization of IGFBP-5 in the
T47D breast cancer cell line and in paraffin sections of involu-
ting mammary glands [33]. To evaluate cellular localization of
IGFBP-5, they used different mutant forms of the protein,
such as signaling peptide and NLS deletions, in addition to
the wild-type secreted form and the recombinant IGFBP-5
protein. They found that cellular localization of IGFBP-5 is
strictly affected by secretion and the nonsecreted form of the
protein. Although IGFBP-5 could not be localized in the
nucleus under in vivo conditions, only the signaling peptide
mutant and the signaling peptide plus NLS mutant forms
were detected in the nuclear compartment and in both
cellular compartments, respectively. Their study emphasizes
the importance of intracellular trafficking of IGFBP-5 and its
critical regions in mammary epithelium.
The NLS of IGFBP-5 also contains a heparin-binding motif
(consensus sequence BBBXXB, where B is a basic amino
acid and X is any amino acid) between amino acids 206 and
211 (KRKQCK). The heparin-binding motif binds to glycos-
aminoglycan. A stimulatory effect of the IGFBP-5 heparin-
binding motif on the migration of mesangial cells has been
shown by Abrass and colleagues, who also showed that this
effect is inhibited by heparin [34]. In addition to the NLS and
the heparin-binding motif, the C-terminal domain of IGFBP-5
also carries IGF-binding sites. Allan and coworkers have
recently shown that mutations of basic residues in the NLS of
IGFBP-5 significantly reduce the affinity for IGF-I [35]. These
studies shed light on the importance of the NLS of IGFBP-5
on its functional spectrum.
Transcriptional regulation of IGFBP-5
expression
T47D breast cancer cells are IGF responsive because they
express IGF-IR and produce IGFBPs. When these cells were
incubated with IGF-I, a significant increase in IGFBP-5 in the
conditioned medium was observed [36]. In contrast, IGF-I
treatment only slightly increased the level of IGFBP-5 in the
cellular extract. IGF-I treatment had no significant effect on
the IGFBP-5 mRNA level in T47D breast cancer cells [36]. In
addition, blocking the IGF-IR using a specific monoclonal
antibody did not change the results, suggesting that IGF-I
regulates IGFBP-5 through both receptor-dependent and
receptor-independent mechanisms [36].
Kou and colleagues analyzed the promoter sequence of
IGFBP-5 by luciferase assays in the mouse C2 myoblast cell
line, and found that 156 nucleotides upstream of the start
codon is critical for the promoter activity of IGFBP-5 [37,38].
Duan and Clemmons later demonstrated that the binding
sites for transcription factor AP-2 are located 5′ from the
TATA box [39]. AP-2 regulates IGFBP-5 gene expression
through binding the proximal GCCNNNGGG-like sequences
in fibroblasts. They also found that this region of the IGFBP-5
promoter is responsible for the cAMP responsiveness of this
gene. In addition, McCarthy and colleagues showed that
prostaglandin E2 enhances IGFBP-5 gene expression in
primary fetal rat osteoblast cultures through AP-2 sites [40].
Gabbitas and colleagues showed that cortisol decreases
IGFBP-5 transcription, and found that the region responsive
to cortisol is from base pairs –70 to –22 and that E-box
binding proteins or c-myb-related nuclear factors may be
involved in its regulation [41]. These findings were confirmed
by another group: Ji and colleagues reported that potential
cis-acting elements, including CAAT/enhancer-binding
protein and NF-1-related sequences, could increase IGFBP-5
promoter activity in prostaglandin E2-activated osteoblasts
[42]. Yeh and colleagues reported a suppressive effect of
osteogenic protein-1 on IGFBP-5 expression at the trans-
criptional level, and found that this osteogenic protein-1 site
was located within the E-box/c-myb-like motif in fetal rat
calvaria cells [43,44]. Analysis of the IGFBP-5 promoter
region by Tanno and colleagues revealed myb-binding sites
and also serine/threonine kinase-binding-responsive elements
in this part of the promoter region [45]. They suggested that
myb-independent transactivation of the IGFBP-5 promoter in
neuroblastoma cells is via the phosphoinositide 3-kinase/
serine–threonine kinase pathway, probably mediated by
IGF-1R-dependent signals.
IGFBP-5 expression is regulated by a number of other
treatments. Retinoic acids are potent growth-inhibitory and
antiapoptotic agents for both normal cells and tumor cells
[46]. Retinoic acid treatment upregulates IGFBP-5 expres-
sion in different cell lines, including neuroblastoma [47],
cervical cancer [48], and osteoblastic cells [49]. Cesi and
colleagues reported that the CAAT/enhancer-binding protein-
responsive element had a repressive effect on IGFBP-5
transcription in neuroblastoma cells [47]. On the other hand,
studies using the breast cancer cell line T47D [36] and the
prostate cancer cell line PC-3 [50] found that treatment with
retinoic acid reduced the IGFBP-5 level. This difference
could possibly be due to the cell type and context
dependency.
Vitamin D regulates calcium homeostasis and also has
potential antiapoptotic activities [51]. The effects of vitamin D
are mediated through its receptor (VDR), which is known to
be a ligand-activated transcription factor and which regulates
target genes. The receptor also binds another nuclear steroid
receptor, retinoid X receptor, and generates heterodimers
[52]. Rozen and colleagues found that vitamin D and its
compounds increased the expression of IGFBP-5 in con-
Available online http://breast-cancer-research.com/content/10/4/212ditioned medium and also had the same effect on its mRNA
level in the MCF-7 breast cancer cell line [53]. It is possible
that IGFBP-5 contributes to the antiproliferative action of
vitamin D in this breast cancer cell line.
Interactions of IGFBP-5 with other
biomolecules
IGFBP-5 has been shown to interact specifically with a
number of proteins, especially the ECM proteins through the
basic carboxyl-terminal domain of the protein. Some of these
proteins are IGF-dependent proteins, such as the acid-labile
subunit [54,55] and glycosaminoglycan [56-58]. Other
proteins are IGF-independent proteins, such as fibronectin
[59], osteopontin [60], four-and-a-half LIM protein 2 [61],
human plasminogen activator inhibitor-1 [62], thrombospon-
din-1 [60], vitronectin [63,64], importin-β [32], and Ras-
associated domain family 1 protein (RASSF1C) [65]. These
interactions regulate IGF bioavailability and half-life, and
potentiate the physiological roles of IGF.
IGFBP-5 binds to ECM components, such as type III and type
IV collagen, laminin, and fibronectin [66]. This interaction
reduces the affinity of IGFBP-5 for IGF-I and potentiates
growth-stimulatory effects of IGF-I on fibroblasts. Arai and
colleagues investigated the role of glycosaminoglycans in
effecting the interaction of the IGF-I and IGFBP complexes
[57]. They found that heparin, heparin sulfate, and dermatan
sulfate binding to IGFBP-5 resulted in conformational changes
in IGFBP-5 that lowered its affinity for IGF-I and inhibited the
IGF-I:IGFBP-5 interaction. Glycosaminoglycans prevent degra-
dation of IGFBP-5, possibly through the inhibition of some
specific proteases [56]. The heparin-binding motif of IGFBP-5
affects interaction with glycosaminoglycan components of the
ECM. Synthetic peptide models and site-directed mutagenesis
studies have shown that amino acids between 201 and 218 in
the heparin-binding domain of IGFBP-5 are critical residues for
these interactions [57,67]. The same domain also has
migratory induction effects and IGF-binding sites [34,68].
Most circulating IGFs are carried with IGFBPs and a liver-
derived glycoprotein known as the acid-labile subunit. Twigg
and Baxter observed that IGFBP-5 is involved in forming a
ternary complex with IGFs and the acid-labile subunit [54].
Among the six well-characterized IGFBPs, only IGFBP-3 and
IGFBP-5 have the ability to constitute the complex structure.
Interaction sites between IGFBP-5 and the acid-labile subunit
have been identified on the carboxyl-terminal domain of
IGFBP-5 within amino acids 201 to 218 [55]. The central
domain of IGFBP-5 can bind to the acid-labile subunit with
much less potency than full-length recombinant human
IGFBP-5 [69].
Nam and colleagues found that another ECM protein
interacts with IGFBP-5 [60]. Thrombospondin-1 and osteo-
pontin bind to IGFBP-5 and modulate IGF-I-stimulated cell
growth. Moralez and colleagues conducted a detailed
functional analysis of the interaction between IGFBP-5 and
thrombospondin-1 on IGF-I actions [70]. They found that
IGFBP-5 inhibits the binding of thrombospondin-1 to integrin-
associated protein, and this leads to a disturbance of the
cellular response to IGF-I. Plasminogen activator inhibitor-1 is
another ECM component that interacts with IGFBP-5 [62].
Plasminogen activator inhibitor-1 interaction with IGFBP-5
protects the protein from proteolysis. Potential interaction
between IGFBP-5 and vitronectin and its IGF-I-stimulated
biological effects has been investigated in smooth muscle
cells and in MCF-7 breast cancer cells [63,71]. These two
studies found that IGFBP-5 binds vitronectin and enhances
the migration response to IGF-I. A complex of IGF-I–IGFBP-
5–vitronectin also increased cell migration and protein
synthesis in HaCAT keratinocyte cells [64]. Complex
formation between fibronectin and IGFBP-5 does not directly
affect the binding of IGF-I to IGFBP-5 because the binding
sites do not overlap; however, fibronectin increases proteo-
lytic degradation of IGFBP-5 [59]. After this interaction, IGF-
dependent action on cell migration is abolished in mouse
embryonic cells. This different effect of the interaction on
IGFBP-5 protein half-life may depend on the profile of ECM
and may be cell-type specific.
There are also different types of proteins that interact with
IGFBP-5 and determine its IGF-independent effects on
cellular actions. Some of these interacting proteins are
importin-β, four-and-a-half LIM protein 2, and RASSF1C.
IGFBP-5 can transport into the nucleus using a NLS-
dependent pathway mediated by the importin-β nuclear
transport factor [32]. Yeast two-hybrid data provide evidence
that IGFBP-5 interacts with the transcriptional coactivator
protein four-and-a-half LIM protein 2 [61]. These authors
found that these two proteins colocalize into the nucleus in
U2 human osteosarcoma cells. Further studies are needed to
determine the functional role of this interaction. Another novel
interaction with IGFBP-5 has been demonstrated with
RASSF1C, a member of the RASSF1 gene products, by the
same yeast two-hybrid methodology [65]. This interaction
contributes to mediating the effects of IGFBP-5 on extra-
cellular signal-regulated kinase phosphorylation and osteo-
blast cell proliferation.
Involvement of IGF and IGFBP-5 in mammary
gland development and involution
Mammary gland differentiation is a good model for under-
standing the roles of IGFBPs in cancer development. The
growth, development, and regression of the mammary gland
during the cycle of pregnancy, lactation, and involution are
regulated by several factors. Hormones, growth factors, and
the ECM are involved in these processes. One of the most
critical and interesting systems involved in the regulation of
mammary epithelial cell function is the IGF axis [72,73]. IGFs
work coordinately with growth hormone to enhance its
developmental effects on the mammary gland. Generally, all
six IGFBPs are present on the mouse mammary gland, and
Breast Cancer Research    Vol 10 No 4 Akkiprik et al.
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pregnant gland tissue [74]. The expression level of IGFBP-5
increases dramatically during the early stages of involution,
and an apoptotic relationship has been shown by several
laboratories [75-79].
Involution involves two distinct phases. The first phase is
reversible and controlled by apoptosis. The second phase is
irreversible and is characterized by remodeling of the
lobuloalveolar architecture, which is regulated by proteases
and macrophages [80]. Although many critical genes and
pathways – such as NF-κB, phosphoinositide (3)-kinase,
Stat3, transforming growth factor beta [81], matrix metallo-
proteinase, and the TIMP family [80] – are involved in
apoptotic events of involution, the IGFBP-5 gene has recently
been shown to play a crucial role in both stages. The
increases in the IGFBP-5 level are regulated by prolactin
[77], which plays an essential role in the suppression of
IGFBP-5 secretion. There is good homeostasis between
regulation of the IGF axis and involution events. Mechanistic
studies have shown that growth hormone increases IGF-I
synthesis and that prolactin represses IGFBP-5 expression
[78,82]. When prolactin levels are reduced by weaning, Stat3
is activated and the IGFBP-5 level then increases. The find-
ings suggest that an enormous increase of IGFBP-5 in the
involution phase induces mammary epithelial apoptosis [83].
Lochrie and colleagues recently offered another hypothesis
[84]: IGFBP-5 expression has a dual regulation during both
differentiation and apoptosis in the mammary gland, and there
is a spatial regulation of IGFBP-5 function in breast tissue
differentiation and cancer progression. It is conceivable that
the regulation of IGFBP-5 subcellular localization is a key
mechanism in controlling IGFBP-5 function. Ning and
colleagues recently used IGFBP-5 knockout mice to show
the in vivo effects of IGFBP-5 in mammary gland develop-
ment [85]. They found that IGFBP-5 is not essential to normal
growth but does have an important role in mammary gland
involution and also can regulate mammary gland
differentiation by different mechanisms.
Role of IGFBP-5 in breast cancer
Although studies based on breast cancer cell lines have
yielded conflicting data regarding the function of IGFBP-5,
these findings nevertheless offer important insight into the
molecular mechanisms and possible role of IGFBP-5 in
breast cancer. Such information will provide new ideas for
clinical applications and routine usage in breast cancer
therapy, prognosis, and early diagnosis. Most studies related
to IGFBP-5 focus on its apoptotic potential, its interaction
with other proteins, cell migration abilities, enhancement of
cell growth, and cellular trafficking [2,11].
The IGF-I signaling pathway is activated in breast cancer and
activates two main downstream signal transduction path-
ways: the IRS-1/phosphoinositide 3-kinase/serine–threonine
kinase pathway and the Ras/mitogen-activated protein kinase/
extracellular signal-regulated kinase pathway (Figure 2). These
two signaling cascades, which are the most critical pathways
in cancer progression, are responsible for the aggressive
phenotype of breast cancer [86-88]. IGFBP-5 can regulate
these pathways by binding with IGF-I – this is known as the
IGF-dependent effect of the IGF binding proteins (Figure 3a).
In addition to its IGF-dependent function, IGFBP-5 has also
unique functions that are IGF independent. The IGF-
independent effect of IGFBP-5, however, is more compli-
cated than its IGF-dependent effects. IGFBP-5 can bind with
its putative receptor to enter the cell cytoplasm and can then
interact with and regulate the functions of other proteins [89].
Through these protein–protein interactions, IGFBP-5 may
regulate the metastatic capacity (Figure 3b). More than 100
proteins may possibly interact with IGFBP-5, causing it to
acquire novel functional properties.
Genetic variation in the IGFBP-5 gene and
breast cancer risk
There is currently limited information regarding IGFBP5
genetic polymorphisms in breast cancer risk. Garner and
colleagues, however, recently reported a study that showed a
significant association of genetic variation in IGFBP-5 with
breast cancer risk in two independent populations of African
descents [90]. In their study, researchers focused on the
African-American women younger than 40 years of age who
have a higher incidence of breast cancer. It was found that
the polymorphisms in three exons at the 3′ end of IGFBP5
were associated with the increased risk of breast cancer in
African-Americans and Nigerians. The authors proposed that
the genetic variant may alter the expression of the IGFBP in
the cell, the binding of IGF-1 to the IGFBP, the proteolytic
action of the proteases, or the localization of IGFBP5 within
the cell. Additional studies will be needed to evaluate the role
of IGFBP5 polymorphism in breast cancer risk.
Prognostic significance of IGFBP-5 in breast
cancer
The role of IGFBP-5 in human breast cancer is very complex
and is not completely understood. Wood and Yee have
shown that IGFBP-5 is not expressed or is only weakly
expressed in normal breast epithelium cells in adults [74].
Some studies have also found elevated IGFBP-5 levels in
breast cancer tissues [91-93]. Pekonen and colleagues
detected IGFBP-5 mRNA in 47 breast cancer tissue speci-
mens by RT-PCR, and found higher levels of IGFBP-5 content
in the tumor specimens than in adjacent normal tissues [91].
IGFBP-5 was also found in breast cancer tissue samples at
the protein level using ligand blotting [92]. We also observed
that IGFBP-5 protein is overexpressed in breast cancer tissue
samples compared with normal tissues, and that the protein is
localized to the cytoplasm (unpublished data).
In several independent studies, IGFBP-5 was among the
differentially expressed genes that were positively associated
Available online http://breast-cancer-research.com/content/10/4/212
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that IGFBP-5 is one of the 70 signature genes related with a
poor prognosis [94]. Hao and colleagues found that IGFBP-5
was overexpressed in lymph node metastases compared with
the matched primary cancer tissues [9]. In addition, IGFBP-5
was more frequently overexpressed in T1 breast carcinoma
that has lymph node metastasis compared with T1 carcinoma
with no lymph node metastasis. Furthermore, some studies
have shown that the expression of IGFBP-5 is an adverse
prognostic factor and correlates with metastasis of breast
cancer [95,96].
Li and colleagues recently evaluated the prognostic
significance of IGFBP-5 in breast cancer [14]. They found
that the mRNA level of IGFBP-5 correlated positively with the
invasion of axillary lymph nodes and the presence of the
estrogen receptor (ER). Moreover, an increasing IGFBP-5
mRNA level was associated with a poor outcome for breast
cancer patients who had positive lymph nodes and negative
ER. Mita and colleagues also investigated the predictive
effects of IGFBP-5 on prognosis and endocrine therapy
outcome [96]. Their recently published study of a Japanese
population indicated that the IGFBP-5 mRNA level was not
an independent prognostic factor but, when combined with
the IGFBP-4 and ER status, did provide information useful for
clinical application. They found that patients who expressed
low levels of IGFBP-5 and high levels of IGFBP-4 had a
better prognosis only when the breast cancer was ER-
positive. They also observed a negative correlation between
the level of IGFBP-5 mRNA and HER2 overexpression. These
data suggest that IGFBP-5 may play a role in the metastasis
of breast carcinomas. Consistent with this notion, IGFBP-5
has been implicated in the progression of other types of
cancers, including prostate cancer [97] and thyroid cancers
[98]. Table 1 presents the biological roles of IGFBP-5 in
other types of cancers.
Apart from the prognostic value of IGFBP-5, other IGFBP
proteins as well as IGFBP-5 may affect the response to
endocrine therapy in breast cancer. There are studies showing
that activation of signal transduction molecules is important for
resistance to endocrine therapy [99-102]. The results from our
reverse-phase protein lysate microarray assays of 14 breast
cancer cell lines support evidence that there are close
correlations between the ER status, the IGFBP-2 and
IGFBP-5 levels, and the activation of signaling molecules
Breast Cancer Research    Vol 10 No 4 Akkiprik et al.
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Figure 2
Overview of the insulin-like growth factor-I signaling pathway involved in breast cancer. Insulin-like growth factor I (IGF-I) activates both the
Ras/mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K)/serine–threonine kinase (AKT) pathways, and causes cell
growth and proliferation. ERK1/2, extracellular signal-regulated kinase 1/2; GSK, glycogen synthase kinase; IGF-IR, insulin-like growth factor-I
receptor; IRS-1, insulin receptor substrate; MEK1/2, mitogen-activated protein/extracellular signal-regulated kinase kinase; mTOR, mammalian
target of rapamycin; PTEN, phosphatase and tensin homologue; Shc, GRB2, SOS1, adaptor proteins.[103]. For these reasons, IGFBP-5 has emerged as an
important therapeutic target in the treatment of breast cancer.
Is IGFBP-5 a survival factor or a death factor
in breast cancer?
Although the apoptotic potential of IGFBP-5 has been
studied extensively, there is still no consensus about whether
IGFBP-5 induces apoptosis or promotes cell survival. Perks
and colleagues incubated Hs578T breast cancer cells with
apoptotic inducers such as ceramide and RGD-containing
peptide, and then checked for apoptosis using flow
cytometry, the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetra-
zolium bromide (MTT) assay, and morphological assessment
[104]. They found that exogenously added IGFBP-5 has a
protective effect against ceramide-induced apoptosis [104].
This is the first study to show an antiapoptotic effect of
IGFBP-5. The same researcher group also investigated the
antiapoptotic effect of IGFBP-5 in breast cancer. They used
IGF-responsive MCF-7 cells in addition to nonresponsive
Hs578T cells and applied nonglycosylated IGFBP-5, glyco-
sylated IGFBP-5, and mutant IGFBP-5 [105]. They found
similar results between ceramide and all IGFBP-5 forms in
Hs578T cells. In MCF-7 cells, IGFBP-5 might be a contri-
butor to survival effects of IGF in apoptotic stress, which can
be blocked by prevention of interaction with its ligand.
Recently published clinical observations provide supporting
evidence that IGFBP-5 is associated with metastasis and the
aggressive tumor phenotype in breast cancer [9,106].
On the other hand, Butt and colleagues have shown that
IGFBP-5 prevents the growth of human breast cancer cells in
vitro and in vivo [107]. In their study, stable expression of
IGFBP-5 inhibited the growth of tumors derived from
MDA-MB-231 cells by elevated bax and decreased bcl-2 at
the mRNA level. No antiapoptotic effect was identified using
exogenously added intact or proteolytic fragments of IGFBP-5
in their study. They suggested that IGFBP-5 inhibitory effects
have a novel intracrine mechanism. IGFBP-5 also sensitizes
breast cancer cell lines to the inhibitory effects of TNFα by
blocking NF-κB-mediated cell survival signals. Butt and
colleagues also found that IGFBP-5 induced and activated
both caspase 8 and caspase 9 in the MDA-MB-231 breast
cancer cell line [108]. These caspases regulate different
apoptotic pathways, including intrinsic and extrinsic path-
ways. It is possible that functional diversity may arise from its
interacting proteins and may depend on its subcellular
localization. IGFBP-5 modulates apoptosis through more than
one mechanism.
What is the potential effect of IGFBP-5 on cell
attachment and migration in breast cancer?
One of the multifunctional roles of IGFBP-5 is to mediate cell
attachment. McCaig and colleagues analyzed the survival
signaling mechanism of IGFBP-5 against ceramide-induced
cell death [109]. They used specific inhibitors for related
survival pathways, such as sphingosine kinase and protein
kinase C in the Hs578T breast cancer cell line. They
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Figure 3
Effects of insulin-like growth factor binding protein 5 in breast cancer. Schematic presentations of insulin-like growth factor (IGF)-dependent and
IGF-independent effects of insulin-like growth factor binding protein 5 (IGFBP-5) in breast cancer. (a) Main effects of IGFBP-5 dependent on IGF
in breast cancer. IGFBP-5 binds IGF and blocks activation of IGF signaling. If IGFBP-5 is degraded by specific proteases, IGF releases and
activates cell proliferation. IGF-IR, insulin-like growth factor-I receptor. (b) IGFBP-5 enters cells by specific receptors or other pathways and
determines the cell fate with its cellular localization. Left (arrow a): nuclear import of IGFBP-5 – there are two mechanism through which IGFBP-5
enters the nucleus: importin-β (IMPβ)-mediated or diffusion. Right (arrow b): cytoplasmic accumulation of IGFBP-5 by interaction with other
proteins, and stimulation of antiapoptotic effects and metastasis.Breast Cancer Research    Vol 10 No 4 Akkiprik et al.
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Table 1
Biological roles of insulin-like growth factor binding protein 5 (IGFBP-5) in different types of cancer
Source of 
Cancer type tissue or cell line Application of the study or study design Observed functional effects of IGFBP-5 Ref.
Breast T47D Intracellular trafficking Nuclear localization of IGFBP-5  [31]
Hs578T Analysis of mitogenic effect of IGFBP-5 Protective effect against ceramide-induced  [104]
apoptosis
Hs578T Cell attachment applications Cell attachment increased by exogenously  [110]
added IGFBP-5
MDA-MB-231 Cellular localization and apoptotic role of  IGFBP-5 localizes in the nucleus and produces  [107]
IGFBP-5 apoptosis
MDA-MB-231 Role of IGFBP-5 in the apoptotic pathway IGFBP-5 induces and activates caspase 8 and  [108]
caspase 9
Neuroblastoma B104 Characterization of IGFBP-5 proteases A specific serine-metalloprotease for IGFBP-5 [122]
LAN-5, N1E-115 Analysis of IGFBP-5 promoter sites c-Myb and B-Myb enhance IGFBP-5 transcription [45]
LAN-5, SY5Y(N) Micro and small interfering RNAs directed to  Growth inhibition and more prone to apoptosis [123]
IGFBP-5 mRNA
Various types  Retinoic acid-induced differentiation Increased expression of IGFBP-5 [47,124]
of neuroblastoma 
cells 
LAN-5, SY5Y(N) Silencing IGFBP-5 Mitochondrial apoptosis [125]
Prostate CWR22, CaP  Castration and androgen stimulation Androgen receptor upregulates IGFBP-5 [126]
xenograft
Mouse androgen- Castration-induction Upregulation of IGFBP-5 [97]
dependent Shionogi 
tumor model
LNCaP Hormone treatment No significant effect on IGFBP-5 mRNA level [127]
PC-3 1α,25(OH)2D3 treatment IGFBP-5 is primary target gene of the  [128]
1α,25(OH)2D3
Bone marrow  Androgen suppression treatment Increasing IGFBP-5 mRNA expression facilitates  [129]
stromal cells prostate cancer progression
Osteosarcoma Osteosarcoma U2  Proteolytic degradation of IGFBP-4 and  Proteolytic activity of IGFBP-5 can modulate  [130]
cell line, untrans- IGFBP-5 IGF action in bone 
formed normal 
human bone cells
Rat osteosarcoma  Relationship between growth hormone  IGFBP-5 increases growth hormone receptor  [131]
cells receptor and IGFBP-5 mRNA and growth hormone binding and 
potentiates mitogenesis 
OS/50-K8 mouse  Biological activity of IGFBP-5 IGFBP-5 reduces proliferation and regulates  [132]
osteosarcoma cells differentiation
U2 human  Examination of IGFBP-5 proteases ADAM-9 cleaved IGFBP-5 specifically and is  [133]
osteosarcoma cells produced by osteoblast cell types
Bone cells Silencing of IGFBP-5 Knockdown of IGFBP-5 induced DNA synthesis  [134]
and reduced differentiation
U2 human  Detection of IGFBP-5 interacting proteins A novel IGFBP-5 interacting protein (IGFBP5-IP) [135]
osteosarcoma cells
LSaOS human  IGFBP-5 regulations in bone Four-and-a-half LIM protein 2 and ADAM-9 are  [136]
osteosarcoma  major modulators of IGFBP-5 actions
cell line
Ovarian Human ovarian  IGFBP levels Expression of IGFBP-5 appears as a rather  [137]
carcinoma lines rare event
Continued overleafobserved that IGFBP-5 promotes cell attachment and survival
and is affected by signaling pathways. McCaig and
colleagues also used different ECM components – such as
laminin, collagen type IV, and fibronectin – to investigate the
role of IGFBPs in cell attachment in the Hs578T breast
cancer cell line [110]. They found that cell attachment to a
general ECM such as laminin and collagen type IV was
increased by exogenously added IGFBP-5, whereas attach-
ment to fibronectin was decreased by IGFBP-5. They
suggested that the presence of fibronectin in matrix compo-
nents determines cell survival and depends on intrinsic action
of IGFBP-5.
One of the ECM proteins, vitronectin, is critical for some of
the IGF-I-related actions, including DNA synthesis, IGF-IR
autophosphorylation, and cell migration. Kricker and colleagues
investigated potential effects of IGF-I–vitronectin interaction
and the functional roles of IGFBPs [71]. They found that
IGFBP-5 enhanced binding of IGF-I to vitronectin. They also
found that the IGF-I–IGFBP-5–vitronectin complex increases
cell migration in MCF7 cells. Their study also showed an IGF-
I-dependent migration effect of IGFBP-5. Kricker and
colleagues’ findings are consistent with the data from studies
using human breast tissue samples, and support the notion
that IGFBP-5 plays a role in cell migration and invasion of
breast cancer.
Crosstalk between IGFBP-5 and estrogen
receptors in breast cancer
Estrogen and IGFs are major growth regulatory hormones
with similar signal transduction pathways (ligand–receptor
interaction followed by downstream cascade). They have a
synergistic effect on cell proliferation in the MCF-7 breast
cancer cell line. The crosstalks between these two pathways
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Table 1
(continued)
Source of 
Cancer type tissue or cell line Application of the study or study design Observed functional effects of IGFBP-5 Ref.
Ovarian Various types of  Examine IGFBP-2 and IGFBP-5 levels Overexpression of IGFBP-5 in high-grade  [138]
ovarian cancers  ovarian carcinoma
Ovarian cancer  Evaluate predictive value of IGFBPs in  IGFBP-5 is a predictive marker for endocrine  [139]
patients aromatase inhibitor letrozole therapy 
Cervical HPV(–) C33A,  Retinoic acid treatment IGFBP-5 overexpression determines retinoic  [48]
HPV(+) CaSki cells acid effects in human papilloma virus(–) cells
Squamous cell  Cervical carcinogenesis Downregulation of IGFBP-5 [140]
carcinomas
Colon LoVo cells NS398 treatment IGFBP-5 might be a target of NS398 [141]
Colon epithelial  Leptin treatment Downregulation of IGFBP-5 by leptin treatment [142]
cells
Renal Oncocytomas,  Changes of IGF/IGFBPs Downregulation of IGFBP-5 in papillary  [143]
clear cell and  renal cell carcinoma and oncocytomas
papillary renal 
cell carcinoma
Clear cell renal  Analysis of IGF-axis components  Downregulation of IGFBP-5 [144]
cell carcinoma
Lung Lung squamous  Identification of differentially expressed genes Overexpression of IGFBP-5 [145]
cell carcinomas, 
and normal 
bronchial epithelial 
tissues
Gastric A panel of human  Detect IGFs and IGFBP levels One-half of the tumor cells express IGFBP-5 [146]
gastric cancer cell 
lines, and normal 
and tumor tissues
Thyroid Various types of  IGFBP-5 levels Overexpression of IGFBP-5 in papillary carcinoma [98]
thyroid tissues
Pancreas Pancreatic ductal  Differential expression of genes Overexpression of IGFBP-5 [147]
adenocarcinoma
1α,25(OH) 2D3 = 1α,25-dihydroxyvitamin D3; IGF = insulin-like growth factor; IGFBP = insulin-like growth factor binding protein.have been identified and reviewed [111,112]; both systems
and their interactions are related to increased resistance to
hormone therapy and cancer recurrence. Lee and colleagues
have shown that transcriptional activation of the ER is
controlled by IGF-I in breast cancer cells [113]. Estradiol
induced expression of IRS-1, which activates downstream
signaling of IGF-I and potentiates its cell proliferative ability.
Antiestrogens may downregulate IRS-1, which could be one
of the possible mechanisms involved in the development of
the antiestrogen response [114]. IGF-IR mitogenic and non-
mitogenic functions may depend on the ER status in the
breast cancer cell line. In the ER-negative MDA-MB-231
breast cancer cell line, IGF-IR may regulate migration and the
adhesion abilities of these cells; whereas in ER-positive
MCF-7 breast cancer cells, IGF-IR can modulate mitogenic
stimulation [115]. The interactions and communications
between the IGF axis and the ER pathway in breast cancer
are therefore important in the development of breast cancer.
There is also evidence that estrogen regulates IGFBP-5
expression in breast cancers. In vitro studies have shown that
growth inhibition of MCF-7 human breast cancer cells
induced by the antiestrogen ICI 182,780 is associated with
increased transcription of the IGFBP-5 gene and increased
IGFBP-5 protein accumulation in the conditioned medium.
Similar results have been reported by other groups
[116,117]. These data suggest that IGFBP-5 plays a role in
modulating the proliferation of breast cancers by estrogens
and antiestrogens. On the other hand, antiestrogen ICI
164384 has also been shown to transiently decrease the
steady-state mRNA level of IGFBP-5 in T-47D cells [118].
Both estrogens and antiestrogens (ICI 182,780 and
tamoxifen) could enhance the expression of IGFBP-5 in the
MCF-7 breast cancer cell line [119].
In our own studies, we used protein lysate array technology
to analyze the association between IGFBP-5 and ER status
and some signaling proteins, cell cycle proteins, and
apoptotic proteins and their phosphorylation profiles in 14
breast cancer cell lines. We found a positive correlation
between overexpression of IGFBP-5 and the presence of ER
and also downstream signaling pathways in breast cell lines
[103]. Similar findings have been observed in breast cancer
tissues [120]. The mRNA level of IGFBP-5 was greater in ER-
positive cancer tissues than in ER-negative tissues [92]. The
relationship between signal transduction pathways and ER
status was reviewed by Normanno and colleagues [121]. In
the near future, IGFBP-5 will probably be an important
predictive marker for resistance and responses during anti-
estrogen therapy for breast cancer. Some microarray data
support the idea that the IGFBP-5 expression level deter-
mines tamoxifen responsiveness [99].
Conclusions
IGFBP-5 is one of the critical members of the IGF system for
both normal cell physiology and tumorigenesis. IGFBP-5
function is affected by many conditions: presence of the
ligand, interacting proteins, proteolytic degradation, post-
translational modifications, transcriptional regulation, and
cellular localization. Research in the future should result in
new knowledge regarding novel IGFBP-5-interacting proteins,
new tissue-specific proteases, different functional roles of
post-translational modifications on IGFBP-5, transcriptional
regulator genes, and the logic and mechanisms of cellular
trafficking of IGFBP-5 in different types of tumors. When
such future studies are completed and a consensus is
reached regarding the experimental data and related clinical
findings, this protein may well prove to play a role as one of
the most important targets in breast cancer therapeutics.
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